Markets

Galapagos NV Announces Gamgertamig Preliminary Phase 1b Data and Poster Presentation at 2026 ASH Meeting

TradeNews USA cash-and-futures note (2026-11-05): Galapagos NV announced the acceptance of a poster presentation at the 2026 American Society of Hematology Annual Meeting, scheduled for December 12-15,… Primary source: original at Nasdaq (nasdaq.com).

November 4, 2026 8:06 PM ET · Nasdaq

Galapagos NV announced the acceptance of a poster presentation at the 2026 American Society of Hematology Annual Meeting, scheduled for December 12-15, featuring preliminary data for gamgertamig in relapsed/refractory autoimmune cytopenias. Gamgertamig is an investigational BCMAx

Read at source